Replies to post #139052 on Biotech Values

[biomaven0]

>>Will this be an issue especially with the cancer issue they had earlier.

No. Neurontin dosing is often higher and the preclinical cancer issue was a complete red herring.

At this point I don't see the PHN approval as being much of a driver without the GSK situation being sorted out.

Peter